Antitumor Activity of Ficlatuzumab in Combination with Tivozanib On Primary Human Renal Cell Carcinoma Xenografts

被引：0
|
作者：
Meetze, K. [1 ]
Connolly, K. [1 ]
Feng, B. [1 ]
Rideout, W. [1 ]
Gyuris, J. [1 ]
Han, M. [1 ]
机构：
[1] AVEO Pharmaceut Inc, Drug Discovery, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
301
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [11] The role of tivozanib in advanced renal cell carcinoma therapy
    Escudier, Bernard
    Porta, Camillo
    Eisen, Tim
    Belsey, Jonathan
    Gibson, Damilola
    Morgan, Jonathan
    Motzer, Robert
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (11) : 1113 - 1124
  • [12] Tivozanib: a new treatment option for renal cell carcinoma
    Saes, L.
    Eskens, F. A. L. M.
    DRUGS OF TODAY, 2017, 53 (11) : 609 - 618
  • [13] Antitumor activity of IDN 5109, a new taxane, on human ovarian carcinoma xenografts
    Rossi, C
    Mincione, T
    Nicoletti, I
    Bombardelli, E
    Riva, A
    Donati, MB
    Giavazzi, R
    ANNALS OF ONCOLOGY, 1998, 9 : 92 - 92
  • [14] Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
    Wang, X.
    Zhang, L.
    O'Neill, A.
    Bahamon, B.
    Alsop, D. C.
    Mier, J. W.
    Goldberg, S. N.
    Signoretti, S.
    Atkins, M. B.
    Wood, C. G.
    Bhatt, R. S.
    BRITISH JOURNAL OF CANCER, 2013, 108 (02) : 319 - 326
  • [15] Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
    X Wang
    L Zhang
    A O'Neill
    B Bahamon
    D C Alsop
    J W Mier
    S N Goldberg
    S Signoretti
    M B Atkins
    C G Wood
    R S Bhatt
    British Journal of Cancer, 2013, 108 : 319 - 326
  • [16] Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
    Fishman, M. N.
    Srinivas, S.
    Hauke, R. J.
    Amato, R. J.
    Esteves, B.
    Cotreau, M. M.
    Strahs, A. L.
    Slichenmyer, W. J.
    Bhargava, P.
    Kabbinavar, F. F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2841 - 2850
  • [17] TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma
    Albiges, L.
    Barthelemy, P.
    Gross-Goupil, M.
    Negrier, S.
    Needle, M. N.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2021, 32 (01) : 97 - 102
  • [18] Antitumor efficacy of panitumumab alone or in combination with chemotherapy against human pancreatic carcinoma xenografts.
    Bush, T
    Freeman, D
    Ogbagabriel, S
    Ziegler, B
    Belmontes, B
    Van, G
    Johnson, C
    Radinsky, R
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9049S - 9049S
  • [19] Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
    Rodenburg, R. J.
    Eskens, F. A. L. M.
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2019, 12 : 137 - 141
  • [20] Combination of sunitinib and mAb cG250 in nude mice bearing human renal cell carcinoma xenografts
    Oosterwijk-Wakka, J. C.
    Mulders, P. F. A.
    Oosterwijk, E.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E200 - E200
12345